WASHINGTON — They are among the most promising new cancer therapies available, but they come with sky-high prices to match. And now the Trump administration is grappling with just how the federal government, through Medicare and Medicaid, will pay for them.

The government’s payment policies for CAR-T treatments — which cost hundreds of thousands of dollars — are just beginning to take shape, but will likely have trickle-down effects on insurance coverage decisions throughout the country. They will also likely affect how enthusiastically doctors and hospitals start offering the therapies to patients.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy